entertainment -WSS

entertainment

author：hotspot 2025-10-01 21:34:48 - browse：8633

Sammy Kimball for STAT

Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss what some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Affirmative action in medical school literally saved lives
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

WSS

Cassava Sciences’ Alzheimer’s clinical trials should be halted

As AI in medicine takes off, can 'human in the loop' prevent harm?

J&J lung cancer data amount to new salvo against AstraZeneca

UnitedHealth, Optum discontinue NaviHealth name

Results on Novartis prostate cancer therapy could expand its use

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Wikipedia

entertainment

focus

Medicare details structure of new drug price negotiation program

Steward Health Care Massachusetts hospitals face fiscal disaster

State Dept. review finds Biden bears some blame for Afghanistan failures

President Biden's budget: Here's what you might have missed

Bright Health sells Medicare Advantage business to Molina

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

At least 13 dead in Texas as scorching temps continue

UnitedHealth, Optum discontinue NaviHealth name

State Dept. review finds Biden bears some blame for Afghanistan failures

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

leisure time

Roche acquires Telavant from Roivant, adding experimental IBD treatment

John Green on his newest strategy for fighting tuberculosis

FDA clears Verve to begin U.S. study of gene

Ebola: Gilead Sciences antiviral shows promise as new treatment

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

explore

Wikipedia

focus

knowledge